The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD)

There is growing evidence that phagocytosis regulatory factors (PRFs) play important roles in tumor progression, and therefore, identifying and characterizing these factors is crucial for understanding the mechanisms of cellular phagocytosis in tumorigenesis. Our research aimed to comprehensively characterize PRFs in prostate adenocarcinoma (PRAD) and to screen and determine important PRFs in PRAD which may help to inform tumor prognostic and therapeutic signatures based on these key PRFs. Here, we first systematically described the expression of PRFs in PRAD and evaluated their expression patterns and their prognostic value. We then analyzed prognostic phagocytic factors by Cox and Lasso analysis and constructed a phagocytic factor-mediated risk score. We then divided the samples into two groups with significant differences in overall survival (OS) based on the risk score. Then, we performed correlation analysis between the risk score and clinical features, immune infiltration levels, immune characteristics, immune checkpoint expression, IC50 of several classical sensitive drugs, and immunotherapy efficacy. Finally, the Human Protein Atlas (HPA) database was used to determine the protein expression of 18 PRF characteristic genes. The aforementioned results confirmed that multilayer alterations of PRFs were associated with the prognosis of patients with PRAD and the degree of macrophage infiltration. These findings may provide us with potential new therapies for PRAD.

[1]  I. Weissman,et al.  Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis , 2021, Nature.

[2]  Jianwei Zhu,et al.  RPL21 siRNA Blocks Proliferation in Pancreatic Cancer Cells by Inhibiting DNA Replication and Inducing G1 Arrest and Apoptosis , 2020, Frontiers in Oncology.

[3]  L. Chodosh,et al.  CD47 blockade augmentation of Trastuzumab antitumor efficacy dependent upon antibody-dependent-cellular-phagocytosis. , 2019, JCI insight.

[4]  X. Liang,et al.  TRIB3 supports breast cancer stemness by suppressing FOXO1 degradation and enhancing SOX2 transcription , 2019, Nature Communications.

[5]  Hanbyoul Cho,et al.  Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer , 2019, BMC Cancer.

[6]  Feihu Chen,et al.  ROS play an important role in ATPR inducing differentiation and inhibiting proliferation of leukemia cells by regulating the PTEN/PI3K/AKT signaling pathway , 2019, Biological Research.

[7]  J. Varner,et al.  Targeting Tumor-Associated Macrophages in Cancer. , 2019, Trends in immunology.

[8]  H. Baba,et al.  Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. , 2019, European journal of cancer.

[9]  Ji-Young Kim,et al.  FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer , 2018, Nucleic acids research.

[10]  Michael P Snyder,et al.  Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens , 2018, Nature Genetics.

[11]  F. Su,et al.  Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages , 2018, Cell.

[12]  D. Green,et al.  LC3-Associated Phagocytosis in Myeloid Cells Promotes Tumor Immune Tolerance , 2018, Cell.

[13]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[14]  T. Kohno,et al.  The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer. , 2018, Lung cancer.

[15]  Aifeng Zhang,et al.  Apatinib inhibits macrophage-mediated epithelial–mesenchymal transition in lung cancer , 2018, RSC advances.

[16]  E. Ebrahimie,et al.  Computational systems biology analysis of biomarkers in lung cancer; unravelling genomic regions which frequently encode biomarkers, enriched pathways, and new candidates. , 2018, Gene.

[17]  Dong Yang,et al.  miR-103 Functions as a Tumor Suppressor by Directly Targeting Programmed Cell Death 10 in NSCLC , 2018, Oncology research.

[18]  B. Schaar,et al.  Tumor associated macrophages in gynecologic cancers. , 2018, Gynecologic oncology.

[19]  Luyong Zhang,et al.  Paracrine signaling by VEGF‐C promotes non‐small cell lung cancer cell metastasis via recruitment of tumor‐associated macrophages , 2018, Experimental cell research.

[20]  J. Que,et al.  FOXO1: Another avenue for treating digestive malignancy? , 2017, Seminars in cancer biology.

[21]  Sung-Hoon Kim,et al.  Role of Forkhead Box Class O proteins in cancer progression and metastasis. , 2017, Seminars in cancer biology.

[22]  R. Maddaly,et al.  Cancer Cytokines and the Relevance of 3D Cultures for Studying Those Implicated in Human Cancers , 2017, Journal of cellular biochemistry.

[23]  M. Ferrer,et al.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. , 2017, Cancer discovery.

[24]  J. Xiong,et al.  Role of ARPC2 in Human Gastric Cancer , 2017, Mediators of inflammation.

[25]  S. Grinstein,et al.  Diversity and Versatility of Phagocytosis: Roles in Innate Immunity, Tissue Remodeling, and Homeostasis , 2017, Front. Cell. Infect. Microbiol..

[26]  Min A. Jhun,et al.  Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort , 2017, Oncotarget.

[27]  J. Danska,et al.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin , 2017, Nature.

[28]  Ting Wu,et al.  Tumor microenvironment and therapeutic response. , 2017, Cancer letters.

[29]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[30]  N. Zhang,et al.  Up-regulation of GTPBP4 in colorectal carcinoma is responsible for tumor metastasis. , 2016, Biochemical and biophysical research communications.

[31]  Wei Zhang,et al.  MicroRNA‐103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer , 2016, The Prostate.

[32]  R. Montironi,et al.  Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? , 2016, Oncology reviews.

[33]  S. Gordon.  Phagocytosis: An Immunobiologic Process. , 2016, Immunity.

[34]  B. Stevens,et al.  New insights on the role of microglia in synaptic pruning in health and disease , 2016, Current Opinion in Neurobiology.

[35]  Megha Jain,et al.  Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention. , 2016, The Gulf journal of oncology.

[36]  I. Kreitschmann-Andermahr,et al.  Downregulation of programmed cell death 10 is associated with tumor cell proliferation, hyperangiogenesis and peritumoral edema in human glioblastoma , 2015, BMC Cancer.

[37]  A. Kotb,et al.  Sexual activity and the risk of prostate cancer: Review article. , 2015, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[38]  Wenxue Hu,et al.  Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma. , 2015, Oncology letters.

[39]  K. Ravichandran,et al.  Phagocytosis of apoptotic cells in homeostasis , 2015, Nature Immunology.

[40]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[41]  R. Abbasi,et al.  Epigenetic Regulation of Inflammatory Cytokines and Associated Genes in Human Malignancies , 2015, Mediators of inflammation.

[42]  I. Weissman,et al.  Macrophages are critical effectors of antibody therapies for cancer , 2015, mAbs.

[43]  H. Dvorak.  Tumors: Wounds That Do Not Heal—Redux , 2015, Cancer Immunology Research.

[44]  Huaxi Xu,et al.  Depletion of C3orf1/TIMMDC1 Inhibits Migration and Proliferation in 95D Lung Carcinoma Cells , 2014, International journal of molecular sciences.

[45]  S. Knight.  Decision making and prostate cancer screening. , 2014, The Urologic clinics of North America.

[46]  E. Giannoni,et al.  The Role of M1 and M2 Macrophages in Prostate Cancer in relation to Extracapsular Tumor Extension and Biochemical Recurrence after Radical Prostatectomy , 2014, BioMed research international.

[47]  Jeong-Hoon Cho,et al.  Nucleolar GTPase NOG-1 Regulates Development, Fat Storage, and Longevity through Insulin/IGF Signaling in C. elegans , 2014, Molecules and cells.

[48]  Y. Pawitan,et al.  An expression signature at diagnosis to estimate prostate cancer patients' overall survival , 2014, Prostate Cancer and Prostatic Disease.

[49]  Stephen J. Smith,et al.  Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways , 2013, Nature.

[50]  C. Galet,et al.  Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. , 2013, American Journal of Cancer Research.

[51]  D. Quail,et al.  Microenvironmental regulation of tumor progression and metastasis , 2014 .

[52]  B. Vickery,et al.  Apoptotic Cell Clearance by Bronchial Epithelial Cells Critically Influences Airway Inflammation , 2013, Pediatrics.

[53]  Ira Mellman,et al.  Antibody Therapeutics in Cancer , 2013, Science.

[54]  H. Scher,et al.  Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  L. Borish,et al.  Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation , 2012, Nature.

[56]  B. Baradaran,et al.  Future prospects of monoclonal antibodies as magic bullets in immunotherapy. , 2013, Human antibodies.

[57]  Chi-Chen Lin,et al.  Brief report: amelioration of collagen-induced arthritis in mice by lentivirus-mediated silencing of microRNA-223. , 2012, Arthritis and rheumatism.

[58]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[59]  K. Aozasa,et al.  Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer , 2011, BJU international.

[60]  Liang Cheng,et al.  FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. , 2011, Cancer research.

[61]  H. Komatsu.  [Antibody therapy in cancer]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[62]  Paolo Provero,et al.  A genome-scale protein interaction profile of Drosophila p53 uncovers additional nodes of the human p53 network , 2010, Proceedings of the National Academy of Sciences.

[63]  A. Mes-Masson,et al.  Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. , 2009, Journal of immunological methods.

[64]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[65]  W. Zhong,et al.  Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis , 2007, The Prostate.

[66]  P. Allavena,et al.  Role of tumor-associated macrophages in tumor progression and invasion , 2006, Cancer and Metastasis Reviews.

[67]  C. Kocks,et al.  Eater, a Transmembrane Protein Mediating Phagocytosis of Bacterial Pathogens in Drosophila , 2005, Cell.

[68]  Norbert Perrimon,et al.  Drosophila RNAi Screen Reveals CD36 Family Member Required for Mycobacterial Infection , 2005, Science.

[69]  M. Nakao,et al.  Epidemiological study of prostatic cancer by matched‐pair analysis , 1986, The Prostate.

[70]  W. Spector.  Chronic inflammation. , 1977, Journal of endodontics.